Polpharma Biologics has said it is the first company to get approval in the EU for a biosimilar version of Biogen’s blockbuster multiple sclerosis therapy Tysabri.
Novartis confirmed this morning that it expects to complete the separation of its generic and biosimilar medicines unit Sandoz into an independent company on or around 4th
CVS Health has made a move on the US biosimilars category with the launch of Cordavis, a new business unit that will work with other drugmakers to bring private-label bios
Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overc
Recently, pharmaphorum spoke with Sebastian Katz, chief strategy officer of specialty healthcare company Stein Holding Group (SteinCares), to discuss the announcement of its licensing agree
AbbVie is preparing to file for accelerated approval of telisotuzumab vedotin (Teliso-V) as a treatment for some patients with lung cancer after the drug hit the mark in a
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio